MedPath

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe

Phase 4
Completed
Conditions
Coronary Disease
Coronary Artery Disease
Coronary Restenosis
Interventions
Device: XIENCE V® Everolimus Eluting Coronary Stent
Registration Number
NCT00402272
Lead Sponsor
Abbott Medical Devices
Brief Summary

The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery lesions.

Detailed Description

The SPIRIT V Clinical Evaluation consists of two concurrent studies,the Diabetic Sub-Study and the Registry.

The SPIRIT V Registry is a prospective, single arm, multi-center registry evaluating performance of the XIENCE V® EECSS in real-world use, per its Instruction For Use (IFU). 2,700 patients will be enrolled in the SPIRIT V Registry.

The long term safety and efficacy of the XIENCE V EECSS have been demonstrated in the SPIRIT FIRST trial up to 5 years, the SPIRIT II trial up to 4 years, and in the SPIRIT III Randomized Control Trial (RCT) up to 3 years. In addition, these pre-approval studies have shown low rates of Target Vessel Failure and Major Adverse Cardiac Events (MACE) that were observed to plateau or gradually decline after about 1 year and were consistently lower than the comparator arm of each study. This benefit in MACE is sustained for up to 5 years and is also independent of the first year results.

The post approval SPIRIT V study demonstrated that the use of the XIENCE EECSS in complex lesions in a real-world population resulted in 1 year MACE, Stent Thrombosis and Target Lesion Revascularization rates that are comparable to those of the previously mentioned pre-approval studies which included patients with more restricted inclusion / exclusion criteria.

Therefore, based on existing data from these trials, Abbott Vascular has decided to discontinue further follow up in the SPIRIT V Registry study after 2 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2700
Inclusion Criteria
  • at least 18 years
  • able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the XIENCE V® EECSS and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure, as approved by the appropriate Medical Ethics Committee of the respective clinical site
  • evidence of myocardial ischemia
  • acceptable candidate for coronary artery bypass graft (CABG) surgery
  • undergo all CIP-required follow-up examinations
  • artery morphology and disease is suitable to be optimally treated with a maximum of 4 planned XIENCE V® EESCC
  • target lesions must be de novo lesions
  • target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate
  • target lesion ≤ 28 mm in length by visual estimate
Exclusion Criteria

Patient is already participating in another device or drug study or has completed the follow-up phase of another study within the last 30 days.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1XIENCE V® Everolimus Eluting Coronary StentXIENCE V® Everolimus Eluting Coronary Stent System
Primary Outcome Measures
NameTimeMethod
SPIRIT V Registry: Adjudicated Composite rate of All Death, Myocardial Infarction (MI) and Target Vessel Revascularization (TVR) .at 30 days
Secondary Outcome Measures
NameTimeMethod
SPIRIT V Registry: Acute Success (Clinical Procedure Success)Acute
SPIRIT V Registry: Adjudicated Stent Thrombosis (Confirmed/definite, Probable, Possible)at 30 days, 1 and 2 years
SPIRIT V Registry: Adjudicated Revascularizations (TLR/TVR/any Revascularization)at 30 days, 1 and 2 years
SPIRIT V Registry: Adjudicated Composite rate of Cardiac Death, MI attributed to the target vessel and TLRat 30 days, 1 and 2 years
SPIRIT V Registry: Adjudicated Composite rate of All Death, any MI and TVRat 30 days, 1 and 2 years
SPIRIT V Registry: Adjudicated Composite rate of All Death, any MI and any Revascularization(TLR/TVR/non TVR)at 30 days, 1 and 2 years
SPIRIT V Registry: Acute Success (Clinical Device Success)Acute

Trial Locations

Locations (93)

Herzzentrum Siegburg GmbH

🇩🇪

Siegburg, Germany

Krishna Heart Institute

🇮🇳

Ahmedabad, India

Meixoeiro-Medtec

🇪🇸

Vigo, Spain

C.H.U. - Hopital Michallon

🇫🇷

Grenoble, France

ULB Erasmus Hospital

🇧🇪

Brussels, Belgium

UZ Gent

🇧🇪

Gent, Belgium

NCN - Nouvelle Cliniques Nantaises

🇫🇷

Nantes, France

Montreal Heart Institute

🇨🇦

Montreal, Canada

La pitié Salpétrière

🇫🇷

Paris, France

Sunnybrook and Women's College

🇨🇦

Toronto, Canada

Prince of Wales Hospital

🇨🇳

Hong Kong, China

Apollo Hospital

🇮🇳

Chennai, India

Polyclinique St Laurent

🇫🇷

Rennes, France

CHUM Hotel Dieu Hospital

🇨🇦

Montreal, Canada

Kerckhoff Klinik GmbH

🇩🇪

Bad Nauheim, Germany

Foothills Medical Center

🇨🇦

Calgary, Canada

Queen Elizabeth

🇨🇳

Hong Kong, China

Policlinica Gipuzkoa

🇪🇸

San Sebastian, Spain

Hospital Virgen de la Arrixaca

🇪🇸

Murcia, Spain

Hopital St Joseph

🇧🇪

Gilly, Belgium

Uppsala Univ. Hospital

🇸🇪

Uppsala, Sweden

Hospital Son Dureta

🇪🇸

Palma de Mallorca, Spain

Wythenshawe Hospital

🇬🇧

Manchester, United Kingdom

King's College Hospital

🇬🇧

London, United Kingdom

University of Ottawa Heart Institute

🇨🇦

Ottawa, Canada

Clinique St. Luc - Bouge

🇧🇪

Namur, Belgium

Marques de Valdecilla

🇪🇸

Santander, Spain

Glenfield Hospital

🇬🇧

Leicester, United Kingdom

Centre Hospitalier Universitaire Vaudois

🇨🇭

Lausanne, Switzerland

Wessex Cardiac Unit

🇬🇧

Southampton, United Kingdom

Bhumibol Adulyadej Hospital

🇹🇭

Bangkok, Thailand

Royal Sussex County, Brighton

🇬🇧

Brighton, United Kingdom

Emodinamica Azienda Spedali Civili

🇮🇹

Brescia, Italy

Ospedale Civile

🇮🇹

Mirano, Italy

Zhongshan Hospital

🇨🇳

Shangai, China

Policlinico A. Gemelli

🇮🇹

Roma, Italy

Puerta del Mar

🇪🇸

Cadiz, Spain

Salzburger Landeskliniken

🇦🇹

Salzburg, Austria

Fuwai Hospital

🇨🇳

Beijing, China

PYNEH

🇨🇳

Hong Kong, China

University health Network - Toronto Gen Hospital

🇨🇦

Toronto, Canada

Hôpital Laval

🇨🇦

Quebec, Canada

Hopital privé Les Fransiscaines

🇫🇷

Nimes, France

CHU Lille - Hôpital Cardiologique

🇫🇷

Lille, France

Lukas Krankenhaus Neuss

🇩🇪

Neuss, Germany

Universitätsklinikum

🇩🇪

Heidelberg, Germany

Universitätsklinikum Ulm

🇩🇪

Ulm, Germany

C.C.N.

🇫🇷

Saint Denis, France

Herzzentrum

🇩🇪

Bernau, Germany

Helios Klinikum Wuppertal

🇩🇪

Wuppertal, Germany

Onassis Cardiac Center

🇬🇷

Athens, Greece

All India Institute of Medical Science - AIIMS

🇮🇳

Delhi, India

Institute of Cardiovascular Disease M.M.M.

🇮🇳

Chennai, India

University Hospital Galway

🇮🇪

Galway, Ireland

Hadassah-Hebrew University Medical Center

🇮🇱

Jerusalem, Israel

B M Birla

🇮🇳

Kolkata, India

Fortis Hospital

🇮🇳

Delhi, India

Kailash Hospital

🇮🇳

New Delhi, India

Azienda Ospedaliera G. Brotzu

🇮🇹

Cagliari, Italy

Beaumont Hospital

🇮🇪

Dublin, Ireland

Azienda USL 8

🇮🇹

Arezzo, Italy

Ichilov Medical Center

🇮🇱

Tel-Aviv, Israel

Azienda Ospedaliera Riuniti

🇮🇹

Bergamo, Italy

Emodinamica Cardiologia Azienda ULSS 12 Veneziana, Ospedale Civile Umberto 1

🇮🇹

Mestre, Italy

Azienda Ospedaliera di Padova

🇮🇹

Padova, Italy

IRCCS Policlinico San Matteo

🇮🇹

Pavia, Italy

Ospedale San Filippo Neri

🇮🇹

Roma, Italy

Azienda Ospedaliera S. Gdi Dio Salerno

🇮🇹

Salerno, Italy

Medisch Centrum Alkmaar

🇳🇱

Alkmaar, Netherlands

Sarawak General Hospital

🇲🇾

Kuching, Malaysia

Christchurch Hospital

🇳🇿

Christchurch, New Zealand

Hospital del Mar

🇪🇸

Barcelona, Spain

Vergelegen Clinic

🇿🇦

Vergelegen, South Africa

Sunninghill Hospital

🇿🇦

Johannesburg, South Africa

Hospital Santa Marta

🇵🇹

Lisboa, Portugal

Hospital Universitari de Bellvigte

🇪🇸

Barcelona, Spain

Hospital Santa Creu I Sant Pau

🇪🇸

Barcelona, Spain

Trias Y Pujol

🇪🇸

Barcelona, Spain

Hospital Puerta de Hierro

🇪🇸

Madrid, Spain

Clinico San Carlos

🇪🇸

Madrid, Spain

Valle Hebron

🇪🇸

Barcelona, Spain

La Paz

🇪🇸

Madrid, Spain

King Chulalongkorn Memorial Hospital

🇹🇭

Bangkok, Thailand

Sheba Medical Center

🇮🇱

Ramat Gan, Israel

Hospital Santa Cruz

🇵🇹

Lisbon, Portugal

National University Hospital

🇸🇬

Singapore, Singapore

UCL St Luc

🇧🇪

Brussels, Belgium

Univerzity Hospital Hradec Králové

🇨🇿

Karlove, Czech Republic

Institute Jantung Negara

🇲🇾

Kuala Lumpur, Malaysia

Catharina ZH Eindhoven

🇳🇱

Eindhoven, Netherlands

Maasstad Ziekenhuis

🇳🇱

Rotterdam, Netherlands

Hospital Garcia da Orta

🇵🇹

Lisbon, Portugal

Ruby Hall Clinic

🇮🇳

Pune, India

© Copyright 2025. All Rights Reserved by MedPath